Imagine your immune system is like a security team that attacks a new organ because it looks like an intruder. Instead of shutting down the whole security team with drugs, this technology uses tiny particles to 're-train' the guards. It teaches them to recognize the new organ as a friend, keeping the organ safe without leaving the rest of the body vulnerable to disease.
Organ transplant patients currently face a choice between the risk of graft rejection or the severe side effects of life-long systemic immunosuppression, such as cancer and infection.
A nano-immunotherapy platform consisting of nanoparticles coated with ligand-loaded MHC molecules designed to reprogram anti-graft immune cells into regulatory cells.
If you are a biotech drug developer dealing with the high failure rate of current immunosuppressants — this project developed a nano-immunotherapy that reprograms immune cells to tolerate grafts. This allows for local protection of the organ without the systemic side effects of traditional drugs.
If you are a clinic provider dealing with a 20% rate of long-term graft failure — this project developed a nanoparticle delivery system that induces tolerance. This could significantly reduce the long-term complications and graft loss for kidney and liver patients.
If you are an SME dealing with the challenge of targeted immune modulation — this project developed a platform using protein-coated nanoparticles to redirect immune responses. This provides a validated method for delivering self-antigens to induce regulation.
Based on available project data, there is no information regarding the cost or pricing of the therapy.
The project has established a molecular engineering pipeline for immune-protein synthesis to enable future clinical translation, but full industrial scale-up data is not provided.
Based on available project data, specific patent or licensing details are not mentioned, though the project builds on previously published work regarding autoreactive T cell responses.
The project runs from 2023-04-01 to 2026-09-30, with the goal of laying the foundation for human clinical trials immediately after the project ends.
The therapy is designed to be delivered local to the transplanted organ to create a tolerogenic environment without systemic effects.
The consortium consists of 5 partners across 4 countries (IT, ES, FR, IE). It is heavily research-oriented with 3 research organizations and 1 university, but includes 1 SME, resulting in a 20% industry ratio. This structure suggests a strong academic foundation with a focused path toward commercial translation via the SME partner.
Contact the Istituto di Ricerche Farmacologiche Mario Negri in Italy
Contact SciTransfer for a detailed analysis of the nano-immunotherapy pipeline.
